View in EDS

Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer

Saved in:
Bibliographic Details
Title: Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer
Authors: Hao-fan Wang, Sha-sha Wang, Mei-chang Huang, Xin-hua Liang, Ya-Jie Tang, Ya-ling Tang
Source: Frontiers in Oncology, Vol 9 (2019)
Publisher Information: Frontiers Media S.A., 2019.
Publication Year: 2019
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: cancer dormancy, immune-mediated dormancy, metastases, disseminated tumor cells (DTCs), immunotherapies, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Description: Immune-mediated dormancy is when the immune system keeps proliferating tumor cells unchanged, mostly via cytotoxic activity of immune cells. Cancer dormancy, especially immune-mediated dormancy, may be the explanation for tumor refractory and may be responsible for resistance to conventional chemo- and radiotherapies. Here, we will describe different scenarios as to how the immune cells and cytokines involved in cancer progression are connected with the initiation of dormancy and cancer treatment. Two distinct treatment methods, such as maintaining metastatic tumor cells dormant and awakening them, are also discussed. A better understanding of immune-mediated dormancy will help to design novel and effective immunotherapies and will likely increase the efficiency of tumor treatment inhibiting metastasis.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/article/10.3389/fonc.2019.00498/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2019.00498
Access URL: https://doaj.org/article/dc4a660d1a2041d9a050628778bd6481
Accession Number: edsdoj.4a660d1a2041d9a050628778bd6481
Database: Directory of Open Access Journals
Description
Abstract:Immune-mediated dormancy is when the immune system keeps proliferating tumor cells unchanged, mostly via cytotoxic activity of immune cells. Cancer dormancy, especially immune-mediated dormancy, may be the explanation for tumor refractory and may be responsible for resistance to conventional chemo- and radiotherapies. Here, we will describe different scenarios as to how the immune cells and cytokines involved in cancer progression are connected with the initiation of dormancy and cancer treatment. Two distinct treatment methods, such as maintaining metastatic tumor cells dormant and awakening them, are also discussed. A better understanding of immune-mediated dormancy will help to design novel and effective immunotherapies and will likely increase the efficiency of tumor treatment inhibiting metastasis.
ISSN:2234943X
DOI:10.3389/fonc.2019.00498